ClinicalTrials.govpublic full text
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
androgen-independent prostatic cancer, androgen-independent prostatic neoplasms, prostate cancer recurrent, androgen-insensitive prostatic cance, androgen-resistant prostatic cancer, hormone refractory prostatic cancer, immunotherapy, immune checkpoint inhibitor, inhibitory checkpoint molecule, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 896424
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.